{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T20:55:10Z","timestamp":1789419310489,"version":"build-2803163510"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.ejmech.2024.116897","type":"journal-article","created":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T15:41:36Z","timestamp":1726933296000},"page":"116897","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Discovery of non-antiproliferative selective estrogen receptor degraders (SERDs) based on scaffold optimization of elacestrant"],"prefix":"10.1016","volume":"279","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6170-6013","authenticated-orcid":false,"given":"Yunlong","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanglong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianpeng","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wukun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejmech.2024.116897_bib1","first-page":"12","volume":"74","author":"Siegel","year":"2024","journal-title":"Cancer statistics, 2024. CA: A Cancer Journal for Clinicians"},{"key":"10.1016\/j.ejmech.2024.116897_bib2","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev-med-070909-182917","article-title":"Mechanisms of endocrine resistance in breast cancer","volume":"62","author":"Osborne","year":"2011","journal-title":"Annu. Rev. Med."},{"issue":"24","key":"10.1016\/j.ejmech.2024.116897_bib3","doi-asserted-by":"crossref","first-page":"15094","DOI":"10.1021\/acs.jmedchem.0c00913","article-title":"Selective estrogen receptor degraders (SERDs): a promising strategy for estrogen receptor positive endocrine-resistant breast cancer","volume":"63","author":"Lu","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116897_bib4","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.mce.2015.08.007","article-title":"The estrogen receptor alpha nuclear localization sequence is critical for fulvestrant-induced degradation of the receptor","volume":"415","author":"Casa","year":"2015","journal-title":"Mol. Cell. Endocrinol."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116897_bib5","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1158\/2159-8290.CD-14-0697","article-title":"Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer","volume":"5","author":"van Kruchten","year":"2015","journal-title":"Cancer Discov."},{"issue":"3","key":"10.1016\/j.ejmech.2024.116897_bib6","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ejca.2007.11.007","article-title":"Effects of fulvestrant 750mg in premenopausal women with oestrogen-receptor-positive primary breast cancer","volume":"44","author":"Young","year":"2008","journal-title":"Eur. J. Cancer"},{"issue":"12","key":"10.1016\/j.ejmech.2024.116897_bib7","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1021\/acs.jmedchem.5b00054","article-title":"Identification of GDC-0810 (ARN-810), an Orally bioavailable selective estrogen receptor degrader (SERD) that demonstrates robust activity in tamoxifen-resistant breast cancer xenografts","volume":"58","author":"Lai","year":"2015","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116897_bib8","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1021\/acsmedchemlett.8b00414","article-title":"Maximizing ER-\u03b1 degradation maximizes activity in a tamoxifen-resistant breast cancer model: identification of GDC-0927","volume":"10","author":"Kahraman","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"issue":"16","key":"10.1016\/j.ejmech.2024.116897_bib9","doi-asserted-by":"crossref","first-page":"11841","DOI":"10.1021\/acs.jmedchem.1c00847","article-title":"GDC-9545 (Giredestrant): a potent and orally bioavailable selective estrogen receptor antagonist and degrader with an exceptional preclinical profile for ER+ breast cancer","volume":"64","author":"Liang","year":"2021","journal-title":"J. Med. Chem."},{"issue":"20","key":"10.1016\/j.ejmech.2024.116897_bib10","doi-asserted-by":"crossref","first-page":"8128","DOI":"10.1021\/acs.jmedchem.5b00984","volume":"58","author":"De Savi","year":"2015","journal-title":"J. Med. Chem."},{"issue":"23","key":"10.1016\/j.ejmech.2024.116897_bib11","doi-asserted-by":"crossref","first-page":"14530","DOI":"10.1021\/acs.jmedchem.0c01163","article-title":"Discovery of AZD9833, a potent and orally bioavailable selective estrogen receptor degrader and antagonist","volume":"63","author":"Scott","year":"2020","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.ejmech.2024.116897_bib12","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1021\/acs.jmedchem.7b01682","article-title":"Discovery of LSZ102, a potent, orally bioavailable selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor positive breast cancer","volume":"61","author":"Tria","year":"2018","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2024.116897_bib13","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1021\/acs.jmedchem.9b01293","volume":"63","author":"El-Ahmad","year":"2020","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2024.116897_bib14","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1021\/acs.jmedchem.6b01355","article-title":"Novel selective estrogen receptor downregulators (SERDs) developed against treatment-resistant breast cancer","volume":"60","author":"Xiong","year":"2017","journal-title":"J. Med. Chem."},{"issue":"24","key":"10.1016\/j.ejmech.2024.116897_bib15","doi-asserted-by":"crossref","first-page":"11301","DOI":"10.1021\/acs.jmedchem.9b01580","article-title":"Design and synthesis of basic selective estrogen receptor degraders for endocrine therapy resistant breast cancer","volume":"62","author":"Lu","year":"2019","journal-title":"J. Med. Chem."},{"issue":"28","key":"10.1016\/j.ejmech.2024.116897_bib16","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1200\/JCO.22.00338","article-title":"Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor\u2013positive, human epidermal growth factor receptor 2\u2013negative advanced breast cancer: results from the randomized phase III EMERALD trial","volume":"40","author":"Bidard","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.ejmech.2024.116897_bib17","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1177\/1758834017711097","article-title":"Fulvestrant in advanced breast cancer: evidence to date and place in therapy","volume":"9","author":"Bo\u00e9r","year":"2017","journal-title":"Therapeutic Advances in Medical Oncology"},{"issue":"16","key":"10.1016\/j.ejmech.2024.116897_bib18","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.1158\/1078-0432.CCR-16-2561","article-title":"Elacestrant (RAD1901), a selective estrogen receptor degrader (SERD), has antitumor activity in multiple ER+ breast cancer patient-derived xenograft models","volume":"23","author":"Bihani","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116897_bib19","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s13058-019-1230-0","article-title":"Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4\/6 inhibitors","volume":"21","author":"Patel","year":"2019","journal-title":"Breast Cancer Res."},{"issue":"2","key":"10.1016\/j.ejmech.2024.116897_bib20","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00280-023-04550-7","article-title":"Pharmacology and pharmacokinetics of elacestrant","volume":"92","author":"Beumer","year":"2023","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"7","key":"10.1016\/j.ejmech.2024.116897_bib21","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1007\/s00044-023-03073-3","article-title":"Harnessing the necessary nitrogen atom in chemical biology and drug discovery","volume":"32","author":"Pennington","year":"2023","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.ejmech.2024.116897_bib22","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.37161","article-title":"The SERM\/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells","volume":"7","author":"Fanning","year":"2018","journal-title":"Elife"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424007785?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424007785?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,10]],"date-time":"2024-11-10T20:41:08Z","timestamp":1731271268000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523424007785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":22,"alternative-id":["S0223523424007785"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116897","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of non-antiproliferative selective estrogen receptor degraders (SERDs) based on scaffold optimization of elacestrant","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116897","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116897"}}